Association of Continuous Subcutaneous Insulin Injection Pumps with Lower HbA1c and Mortality in Type 1 Diabetes of Chronic Duration (1728-P)

Continuous subcutaneous insulin infusion pumps (CSII) may improve HbA1c and quality of life relative to the use of multiple daily injections (MDI) in individuals with type 1 diabetes (T1D), yet there is limited information about the relationship of CSII to mortality. The 50-Year Medalist Study provides a unique opportunity to investigate in 944 individuals with more than 50 y of T1D (mean duration = 53 y, HbA1c = 7.1%, age = 65 y, age at onset = 11 y, daily insulin dose = 0.43 u/kg; 59% use CSII, 49% for 10 y or longer).